000 08078nam a22005535i 4500
001 978-3-031-66754-1
003 DE-He213
005 20251030114555.0
007 cr nn 008mamaa
008 241201s2024 sz | s |||| 0|eng d
020 _a9783031667541
_9978-3-031-66754-1
024 7 _a10.1007/978-3-031-66754-1
_2doi
050 4 _aRC870-923.2
072 7 _aMJS
_2bicssc
072 7 _aMED088000
_2bisacsh
072 7 _aMJS
_2thema
245 1 0 _aImaging and Focal Therapy of Early Prostate Cancer
_h[electronic resource] /
_cedited by Thomas J. Polascik, Jean de la Rosette, Rafael Sanchez-Salas, Ardeshir R. Rastinehad.
250 _a3rd ed. 2024.
264 1 _aCham :
_bSpringer Nature Switzerland :
_bImprint: Springer,
_c2024.
300 _aXXIII, 502 p. 127 illus., 111 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aPart I. Why Consider Focal Therapy? -- 1. What is Focal Therapy for Prostate Cancer? A Guide for Patients -- 2. Evolution of Focal Therapy for Localized Breast Cancer: Lumpectomy -- 3. Image-targeted Therapy for Localized Kidney Cancer -- 4. The Patient’s Perspective: What Does the Patient Want? -- Part II. Global Perspective of Active Surveillance (AS) and Focal Therapy (FT) -- 5. Intersection of AS and Radical Therapy: Opportunities for FT in North America. -- 6. FT and AS of Prostate Cancer - A European Perspective -- 7. FT and AS of Prostate Cancer in Southeast Asia and the East -- 8. FT Perception and Acceptance in South America -- Part III. The Focal Therapy Concept: Scientific Foundation -- 9. Understanding Tumor Biology and Pathology - Cancer Grade, Volume, and Spatial Location – as a Foundation for Focal Therapy -- 10. Identifying and Characterizing the Index Lesion -- 11. The Role of Molecular Techniques to Distinguish Low Grade from Lethal Cancers -- 12. Utilizing Biopsy-based Genomic Assays to Risk Stratify Patients for Active Treatment -- 13. Can Understanding and Utilizing the Tumor Microenvironment Enhance the Therapeutic Efficacy of FT? -- 14. Differences between MRI Visible vs Invisible Cancers: Biology and Outcomes -- Part IV. Prostate Imaging and Staging -- 15. PIRADS Reporting Standards and Limitations for Cancer Detection in the Peripheral Zone vs Transition Zone, PI-QUAL, and Standardization in MR Quality -- 16. Employing a Quality Improvement Program to Optimize mpMRI-directed Fusion Biopsy -- 17. Multiparametric Ultrasound for Prostate Imaging and Targeting -- 18. What is Necessary for FT Staging: Cross-sectional vs PET vs Nil? -- Part V. Image-Targeted Prostate Biopsy Techniques -- 19. mpMRI-TRUS Prostate Fusion Biopsy Commercial Systems.-20. Comparison of Outcomes with Transperineal vs Transrectal Image-targeted Prostate Biopsy -- 21. Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize and Treat the mpMRI Invisible Lesion -- 22. Multi-parametric Ultrasound (mpUS) Biopsy -- 23. Diagnostic Performance of PET-based Targeted Fusion Biopsy in Prostate Cancer -- 24. Optimizing biopsy core quality for diagnosis -- Part VI. Patient Selection and Ablation Treatment Schema -- 25. Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category? -- 26. Definitions and Common Terminology for Focal Prostate Ablation -- 27. Focal Therapy for Anterior Cancers -- 28. Office-based Outpatient Focal Therapy -- Part VII. Transperineal Technologies for Focal Therapy -- 29. Focal Brachytherapy and IMRT -- 30. In-bore Transperineal MRI-Guided Laser Ablation -- 31. Focal Cryoablation -- 32. Irreversible Electroporation for Partial Gland Ablation: Clinical Application and Outcomes -- 33. Photodynamic Therapy -- Part VIII. Transurethral Technologies for Focal Therapy -- 34. Role of TULSA as a Focal Therapy in Prostate Cancer -- 35. Transurethral Vapor Ablation in Prostate Cancer -- Part IX. Transrectal Technologies for Focal Therapy -- 36. Robotic High-Intensity Focused Ultrasound -- 37. Transrectal laser ablation of prostate cancer -- Part X. Post-treatment Assessment of Focal Therapy Outcomes -- 38. Role of Prostate MRI for Post-treatment Assessment and Surveillance -- 39. Measuring patient-based outcomes: setting realistic expectations when balancing functional outcomes with cancer control -- 40. Assessing Functional Outcomes after Focal Therapy -- 41. Biochemical Assessment of Cancer Outcomes following Focal Therapy -- 42. Pathologic Assessment and Implications following Prostate Focal Therapy -- 43. Salvage Options after Focal Therapy Recurrence -- Part XI. Looking forward -- 44. Design of Payment and Reimbursement Strategies for Focal Therapy for Acceptance in Value Based Care Models -- 45. The Horizon: Future of Focal Therapy in Prostate Cancer.
520 _aThis book encompasses an up-to-date, comprehensive review of the state-of-the-art for prostate gland preserving therapies. It provides insight into the latest research and clinical applications of image-guided diagnosis and minimally invasive focal, gland-preserving treatment for prostate cancer. Fully updated and revised, this text evaluates the scientific evidence for the evolving trend to treat intermediate risk, clinically localized prostate cancer in a focally ablative manner with novel gland-preserving, image-targeted therapy methods. Imaging and Focal Therapy of Early Prostate Cancer, Third Edition opens with a discussion of why patients and clinicians should consider focal therapy, then moves on to consider the question of active surveillance versus focal therapy from a global perspective, with chapters on North American, European, Southeast Asian, and South American perspectives. From there, chapters cover the scientific foundation of focal therapy, current and new approaches to image cancer foci within the prostate (multiparametric ultrasonography, multiparametric magnetic resonance imaging, etc.) and various biopsy techniques. Following this is detailed coverage of patient selection, treatment strategy, adjuvants to enhance therapy, outcomes, and patient centered interests, followed by a discussion of the strengths and limitations of various therapeutic modalities, such as cryotherapy, high intensity focused ultrasound, and photodynamic therapy, follows. The final sections of the book cover the assessment of focal therapy outcomes and look forward to the future of focal therapy for prostate cancer. Written by experts in the field and lavishly illustrated with detailed line-art and photographs, this text is designed as a comprehensive resource for urologists, radiation oncologists, medical oncologists, radiologists, uropathologists, molecular biologists, biomedical engineers, residents, fellows, nurses and allied professionals, and researchers with an interest in the diagnosis and novel targeted treatment of prostate cancer.
650 0 _aUrology.
_969549
650 0 _aOncology.
_970760
650 0 _aRadiology.
650 1 4 _aUrology.
_969549
650 2 4 _aOncology.
_970760
650 2 4 _aRadiology.
700 1 _aPolascik, Thomas J.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_988339
700 1 _ade la Rosette, Jean.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_988340
700 1 _aSanchez-Salas, Rafael.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_988341
700 1 _aRastinehad, Ardeshir R.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_988342
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031667534
776 0 8 _iPrinted edition:
_z9783031667558
776 0 8 _iPrinted edition:
_z9783031667565
856 4 0 _uhttps://doi.org/10.1007/978-3-031-66754-1
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c65368
_d65368